Peptide therapy clinics create clinical and documentation gaps when routine intake is treated as patient clearance. A questionnaire or RN-collected history alone may not prove that an authorized provider assessed the patient’s risks and documented a treatment decision before care begins.
This guide explains when an evaluation may be required, who may perform it, what the provider should review, how telehealth works, and what the record should contain. It also covers therapy-specific screening, multi-state workflows, and common compliance failures.
What a Peptide GFE Actually Screens For
A good faith exam before peptide therapy is an individualized clinical evaluation, not an intake form with a provider signature added later. It should bring together:
- The patient’s goals, symptoms, and relevant medical and surgical history
- Current medications, allergies, prior therapies, and adverse reactions
- Available examination findings, vital signs, records, and indicated testing
- Product-specific contraindications, warnings, interactions, and monitoring needs
The emphasis should match the proposed therapy. GLP-1 screening may focus on metabolic history, gastrointestinal symptoms, concurrent diabetes treatment, and product-specific warnings. Growth-hormone-related protocols may require closer attention to endocrine, metabolic, cancer, and screening history.
Other therapies may shift attention toward cardiovascular, sexual-health, neurologic, or medication-interaction concerns. Review the GFE fundamentals for the underlying process.
The Trap: Your GFE Clears the Patient, Not the Peptide
A strong examination can support a candidacy decision, but it cannot resolve the federal and state rules governing a product. Compounding policy, shortage status, bulk-substance eligibility, pharmacy requirements, and state restrictions can change. FDA states that compounded drugs are not FDA-approved. Verify current status through FDA compounding drug guidance, the dispensing pharmacy, and qualified counsel where needed.
| A GFE can document | A GFE does not establish |
| Individual history and risks were reviewed | The product is FDA-approved |
| The provider made a candidacy decision | A substance qualifies for compounding |
| Applicable provider-patient relationship steps were completed | The pharmacy or supplier meets every rule |
| The decision and follow-up were documented | Product status is uniform or permanent |
Peptide Therapy Good Faith Exam Requirements, Point by Point
A good faith exam for peptide therapy clinics should turn state-specific duties into a documented clinical process. Exact rules vary, but defensible peptide therapy good faith exam requirements generally center on these elements:
- Use a qualified clinician. The evaluator needs authority for the patient’s location.
- Evaluate the individual. The provider must assess the actual history, risks, findings, and proposed therapy.
- Establish the clinical basis. Connect the patient’s condition or goals to the candidacy decision.
- Create the required relationship. Satisfy the state’s requirements before ordering treatment.
- Complete it first. Intake, consent, and payment are not clinical clearance.
- Document the plan. Record approval, deferral, denial, referral, monitoring, and follow-up as applicable.
Use AmSpa’s legal requirements overview as a starting point, then confirm the rules with relevant state authorities and counsel.
Who Is Actually Allowed to Sign Off?
Physicians commonly perform GFEs, while physician assistants and nurse practitioners may also perform them when their state license, scope, and supervision or collaboration rules permit. The exact answer depends on where the patient is located, the proposed treatment, and how that jurisdiction defines the required examination and prescribing relationship.
An RN can collect history, medications, vital signs, consent information, and other intake data within scope. That work does not independently replace the qualified prescriber’s evaluation, candidacy decision, treatment order, or documentation. Review qualified GFE providers when assigning each role.
Watch-out: A clinician’s signature on RN-collected intake is not enough if the record does not show the clinician’s own assessment and decision.
Telehealth Good Faith Exam for Peptide Therapy
A telehealth good faith exam for peptide therapy may satisfy an initial-examination requirement in some states when the encounter meets applicable telemedicine standards. The clinician generally must be licensed or otherwise authorized where the patient is located and must use a method capable of supporting the required clinical judgment.
Synchronous video is often the stronger operational default because it allows real-time questioning and observation. Asynchronous questionnaires, photographs, messaging, or recorded clips may be allowed in narrower circumstances, but they are not interchangeable with live evaluation in every state or for every treatment.
Document patient location, identity, consent, modality, history, relevant observations, assessment, and plan. A 30-second video is not defensible simply because video was used. Review the telehealth GFE workflow when designing the process.
Not Every Peptide Clears the Same Way
The GFE before peptide therapy treatment should match the intervention’s risks, not a universal checklist. Screening changes by therapy. NAD+ is not a peptide, although it is often grouped with longevity services. Evidence quality varies significantly by product, so the exam should draw on what’s actually known about that specific therapy, not a general assumption of clinical support.
| Therapy category | What the GFE may emphasize | Common reason to reassess |
| GLP-1-based therapy | Metabolic and gastrointestinal history; medications (see trial population data) | Symptoms, health, or protocol change |
| Sermorelin and related therapy | Endocrine, metabolic, cancer, and screening history | Diagnosis, finding, or elapsed time |
| PT-141 | Cardiovascular, sexual-health, and medication review | Symptoms, medication change, or intolerance |
| NAD+ services | Purpose, comorbidities, route, and prior reaction | Route change, illness, or reaction |
No national rule requires a new GFE for every cycle. Re-evaluation depends on state rules, medical judgment, elapsed time, health changes, and protocol changes.
The Note That Has to Survive a Board Complaint
A GFE is a clinical encounter, not a special form that becomes sufficient when every box is checked. A SOAP-format note, or an equivalent record, should make the provider’s reasoning traceable.
- Subjective: Goals, symptoms, history, medications, allergies, prior therapies, and reactions
- Objective: Identity, location, vital signs, observations, records, and indicated results
- Assessment: Clinical rationale, risks, contraindication review, candidacy decision, and referrals
- Plan: Approval, deferral, or denial; orders; monitoring; precautions; and follow-up
Peptide Therapy GFE Compliance Across Multiple States
Peptide therapy GFE compliance becomes more complex when a clinic sees patients across state lines. Provider scope, telehealth acceptance, consent, prescribing, delegation, examination, and re-evaluation rules can change with the patient’s location. A workflow that works in one state cannot simply be copied nationwide.
For example, a patient may open a telehealth visit while traveling in State B, although the clinic record lists a home address in State A. A provider authorized only in State A may not be able to complete that encounter. Capture the patient’s current physical location, route the case to an appropriately authorized clinician, apply the relevant examination standard, and retain the decision and plan. A state-aware process is more reliable than one universal intake form.
Where Peptide Clinics Get Caught
Most failures begin when operational intake is mistaken for clinical evaluation:
- RN-only intake: No qualified prescriber independently evaluates candidacy or creates the treatment plan.
- Reused checkbox forms: The note does not show how this patient’s history affected the decision.
- No reassessment after change: New symptoms, medications, diagnoses, or protocol changes remain outside the record.
- Out-of-state sign-off: The clinician may lack authority where the patient was physically located.
- Product-status assumption: Staff treat a completed GFE as proof that a compounded product may be sourced or used.
- No explicit decision: The chart contains history and consent but never states approval, deferral, denial, or follow-up.
A process fails when it can show that information was collected but cannot show who exercised clinical judgment, what that judgment was, and which rules applied.
Final Thoughts: Build a Good Faith Exam for Peptide Therapy Clinics Around the Therapy
The defensible standard is not a longer questionnaire. It is an individualized clinical decision, recorded in a SOAP-style or equivalent note, with screening matched to the proposed treatment. A good faith exam before peptide therapy should show why the patient was approved, deferred, denied, referred, or scheduled for follow-up.
At the same time, a good faith exam for peptide therapy clinics must remain separate from the product-status review. Verify compounding, sourcing, prescribing, and state requirements through current authorities. GoodFaithExams.com connects structured intake to qualified provider review and a documented clinical decision without treating the exam as a product-status shortcut. Review the wellness clinic GFE process.
Frequently Asked Questions
Is a Good Faith Exam Required for Peptide Therapy?
In many states, yes, and the evaluation should occur before applicable prescribing or treatment. The rule may instead use terms such as initial examination, patient assessment, or provider-patient relationship. A good faith exam before peptide therapy may apply. Verify the patient’s state and proposed treatment.
What does a provider review during a peptide therapy GFE?
The provider reviews treatment goals, symptoms, diagnoses, medications, allergies, prior reactions, relevant examination findings, contraindications, and available testing or records. The scope should reflect the proposed therapy rather than rely on a universal peptide checklist.
Who is qualified to perform a Good Faith Exam for peptide therapy?
A physician commonly may perform it. An NP or PA may also qualify when state scope, supervision, collaboration, and prescribing rules permit. An RN may support intake but generally cannot replace the authorized provider’s assessment and treatment decision.
Are compounded peptides subject to the same GFE rules as FDA-approved drugs?
The clinical-evaluation requirement and the product’s regulatory status are separate questions. A GFE before peptide therapy treatment does not make a compounded drug FDA-approved or confirm that its substance, pharmacy, prescription, or use satisfies current federal and state rules.
Can a peptide therapy Good Faith Exam be done via telehealth?
Sometimes. A telehealth good faith exam for peptide therapy may be permitted when state law allows the modality, the provider is authorized for the patient’s location, and the technology supports an adequate evaluation. A questionnaire alone may not satisfy the required standard.
What contraindications should a provider identify before peptide therapy?
The provider should identify product-specific contraindications and clinically relevant risks based on the patient’s history, symptoms, medications, examination, and testing. Cardiovascular, metabolic, gastrointestinal, endocrine, cancer-screening, pregnancy, allergy, and interaction concerns may be relevant depending on the therapy.
How does the GFE process differ between different peptide types?
Each therapy shifts the clinical emphasis. GLP-1-based treatment may require greater metabolic and gastrointestinal review, while growth-hormone-related or sexual-health therapies may require different endocrine, cancer-screening, cardiovascular, medication, interaction, monitoring, follow-up, referral, and clinical reassessment considerations.
What documentation must a peptide therapy clinic retain after a GFE?
Retain the history, relevant findings, assessment, candidacy decision, treatment plan, consent documentation, orders, monitoring instructions, and follow-up in accordance with applicable record-retention rules. A SOAP-style note can make the provider’s individualized reasoning easier to trace.
Is a new GFE required for each peptide therapy cycle?
Not under one universal national rule. Re-evaluation depends on state requirements, time elapsed, changes in health or medication, new symptoms, prior response, and changes to the therapy, formulation, dose, route, protocol, or monitoring plan, as appropriate.
What state regulations affect Good Faith Exam requirements for peptide clinics?
Peptide therapy GFE compliance may be affected by provider scope, prescribing authority, telehealth standards, consent, delegation, patient-location rules, examination requirements, and reassessment timing. Check the relevant medical, nursing, pharmacy, and other state authorities before standardizing a workflow.
Can a nurse practitioner perform a Good Faith Exam for peptide therapy?
Often, but not automatically in every state. An NP must act within applicable scope, prescribing authority, collaboration or supervision requirements, and telehealth rules. The patient’s location and the proposed treatment determine which state’s requirements control.
What happens when a clinic administers peptides without a documented GFE?
Without documentation, the clinic may be unable to prove that a qualified provider assessed candidacy. Missing peptide therapy good faith exam requirements can increase board, malpractice, delegation, and recordkeeping exposure. A good faith exam for peptide therapy clinics closes the clinical-record gap, not sourcing issues.
